Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at UC Irvine
Dates
study started
estimated completion

Description

Summary

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.

Official Title

A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Keywords

Alopecia Areata Alopecia CTP-543

Eligibility

You can join if…

Open to people ages 18-65

  • Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial

You CAN'T join if...

  • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis
  • Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication
  • Donation of blood at any point throughout the study and for 30 days after last dose of study medication

Locations

  • University of California, Irvine
    Irvine California 92697 United States
  • Kaiser Permanente Clinical Trials Unit
    San Francisco California 94118 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Concert Pharmaceuticals
ID
NCT03898479
Phase
Phase 2
Study Type
Interventional
Last Updated